Profitable companies and non-Profitable Biotech companies (rising stars) have developed innovative drugs for treatment of chronic and non chronic diseases. In the next five years the distinction between mature biotech companies and large global pharma is likely to disappear as investment in R&D and acquisition start delivering and Market Cap match the large global pharma. Dividend and consolidation could be the future drivers and continue to attract long term investors. Optimism prevails around the future of this sector as a whole which was reflected in the unprecedented rally in shares in 2012.
This trend continued in the next five years driven by launch of Innovative drugs catering to unmet needs in Alzheimer’s, HCV, osteoporosis, RA, Psoriasis, MS, Dyslipidemia, Cystic fibrosis, Cancer and orphan diseases. Drug approvals and label expansion of existing portfolio of launched drugs and data from late stage pipeline drugs should maintain the growth momentum and investors interest.
The early part of the previous decade (2010-20) was spent recovering from the big acquisitions made by this sector but followed by the exercising of some restrain for similar large acquisitions as investors wanted to see the returns reflected in the top-line and EPS. However in- licensing of early or mid stage compounds or small acquisitions continued since the Rising Stars kept throwing the bait by taking risks and innovate using novel technology platforms or validating novel targets for treating diseases.
Patent expiry impact was also modest as majority had “not so easy to copy” biologics and other drugs in their portfolio. They, however were not complacent and were not leaving any stones unturned to meet the challenges as well as exploring emerging market opportunities with local partners. Favorable regulatory environment finally saw biosimilar mAbs entry in regulated markets The optimism of biosimilar players is reflected in the maturing pipeline. Para IV Filing from other generic players continues to pour leaving room for surprises and volatility.
Moving forward the sector should see a strategic rise of the digital mindset and further adoption of transformative and augumentative technologies. While mergers & acquisitions can still expect a sharper focus despite being more traditional, external innovation should result in a meaningful shift in culture through innovative and creative partnerships with both new entrants and less traditional companies.
There will be an increasing demand for even more transparency and disclosure and a need for real relationship-driven partnerships will encroach across all sector stakeholders including regulators, patients, advocacy groups and also to outsourcing players critical to the supply chain. Data will be a dominating force behind new revenue models and crucial to understanding and delivering an exceptional patient experience. Pricing will continue to exert much pressure, increasing access to drugs, growth of gene and cell therapies, and uncertain trade policies will further change the dynamics of the market.
Industry News
- Targeting Nrf2-HMOX1 to Reverse Cisplatin Resistanceby Bioengineer on June 22, 2025 at 2:21 am
In a groundbreaking study poised to shift the paradigm of lung cancer treatment, researchers have uncovered a pivotal pathway that may unlock new therapeutic strategies against cisplatin resistance in non-small cell lung cancer (NSCLC). This research pinpoints the Nrf2-HMOX1 axis as a crucial regulator in mediating resistance to cisplatin chemotherapy, highlighting its role in ferroptosis
- New Translational Read-Through Drugs for Fanconi Anemiaby Bioengineer on June 21, 2025 at 9:39 pm
In a groundbreaking stride toward addressing the complex challenges posed by Fanconi anemia, a genetic disorder marked by progressive bone marrow failure and cancer susceptibility, researchers have unveiled novel therapeutic agents that promise to fundamentally alter treatment landscapes. Published in Cell Death Discovery, the study spearheaded by Hristodor, Cappelli, Baldisseri, and colleagues explores the groundbreaking
- Urban Trees Viewed More Negatively Post-COVID Lockdownsby Bioengineer on June 21, 2025 at 8:10 pm
In the wake of the COVID-19 pandemic, urban environments experienced profound transformations. Among these changes, the public’s interaction with green spaces particularly urban trees, has drawn increasing attention from environmental psychologists and urban planners alike. A recent study published in npj Urban Sustainability by Dade, Livesley, and Barona (2025) reveals a striking shift: people’s perceptions
- Truncated LKB1 Mimics Smac to Boost Fas Apoptosisby Bioengineer on June 21, 2025 at 7:14 pm
In a groundbreaking study published recently in Cell Death Discovery, researchers have unveiled a novel mechanism by which a truncated form of the tumor suppressor kinase LKB1 nonenzymatically amplifies Fas-induced apoptosis. This discovery sheds new light on the intricate regulatory networks governing programmed cell death and suggests promising therapeutic avenues for diseases characterized by aberrant
- Nigral Volume Loss in Early Parkinson’s Stagesby Bioengineer on June 21, 2025 at 6:50 pm
In the relentless quest to understand Parkinson’s disease, a neurodegenerative disorder that affects millions worldwide, recent research has yielded compelling insights into the progressive loss of nigral volume that characterizes different stages of the disease. Emerging findings from Langley, Hwang, Huddleston, and colleagues, published in the prestigious journal npj Parkinson’s Disease, articulate nuanced changes in
- Gasdermin E Drives Pyroptosis Resistance in Glioblastomaby Bioengineer on June 21, 2025 at 2:18 pm
In a groundbreaking study poised to redefine our understanding of glioblastoma biology, researchers have uncovered a paradoxical role of Gasdermin E (GSDME) in this aggressive brain cancer. Traditionally recognized as a crucial mediator of pyroptosis—a highly inflammatory and lytic form of programmed cell death—GSDME has now been found to contribute to glioblastoma’s notorious resistance to
- AI Diagnoses Vocal Cord Paralysis Severityby Bioengineer on June 21, 2025 at 7:10 am
In a groundbreaking advancement at the crossroads of artificial intelligence and clinical otolaryngology, researchers have unveiled an innovative platform that automatically assesses the severity of unilateral vocal cord paralysis (UVCP) using state-of-the-art deep learning techniques. This pioneering research leverages Mel-spectrograms—a sophisticated audio representation technique—paired with convolutional neural networks (CNN) to dissect subtle vocal characteristics, offering
- Humeral Rotation Impacts Rotator Cuff Mechanicsby Bioengineer on June 21, 2025 at 6:04 am
The intricate mechanics of the shoulder have long fascinated biomechanical researchers and clinicians alike, owing to the joint’s remarkable range of motion and complex muscular interplay. Among the critical components contributing to shoulder function is the rotator cuff, a group of muscles and tendons that stabilize the humeral head within the glenoid cavity. Recent research
- Racial Disparities Impact Neonatal Hypoxic-Ischemic Outcomesby Bioengineer on June 21, 2025 at 5:22 am
In a groundbreaking new study published in the Journal of Perinatology, researchers have unearthed unsettling evidence pointing to stark racial disparities in the incidence, severity, treatment, and outcomes of hypoxic-ischemic encephalopathy (HIE) among neonates in the United States. HIE, a devastating form of brain injury caused by oxygen deprivation and limited blood flow shortly before
- Innovative Method for Detecting “Aged” Cells Opens New Frontiers in Ageing Researchby Bioengineer on June 21, 2025 at 4:49 am
Researchers at Tokyo Metropolitan University have pioneered a groundbreaking label-free technique that allows for the precise differentiation of “aged” or senescent human cells from their younger counterparts through the application of alternating electric fields. Conventional methods for identifying senescent cells typically depend on biochemical labeling, such as fluorescent tags that bind to specific markers unique
- Risk Factors for Plastic Bronchitis in Kidsby Bioengineer on June 21, 2025 at 4:46 am
A groundbreaking advancement in pediatric respiratory medicine has emerged with the recent development of a sophisticated predictive model aimed at identifying the risk factors for plastic bronchitis (PB) among children suffering from severe Mycoplasma pneumoniae pneumonia (SMPP). This condition, though uncommon, poses significant risks to young patients, as PB involves the formation of obstructive bronchial
- Seeding-Competent α-Synuclein Aggregates Form in Parkin-Deficient Neuronsby Bioengineer on June 21, 2025 at 2:40 am
In a groundbreaking study recently published in npj Parkinson’s Disease, Schmidt, Okarmus, Madsen, and colleagues have unveiled crucial insights into the molecular underpinnings of Parkinson’s disease (PD) pathology, focusing on the formation of seeding-competent α-synuclein aggregates in parkin-deficient human neurons derived from induced pluripotent stem cells (iPSCs). This novel research elucidates a pivotal mechanistic link
- High-Momentum 2D Emission Coupled to Surface Resonanceby Bioengineer on June 21, 2025 at 1:06 am
In the ever-evolving landscape of photonics and nanophotonics, a groundbreaking study has emerged that pushes the boundaries of our understanding of light-matter interaction at the nanoscale. Researchers Y. Koo, D.K. Oh, J. Mun, and colleagues have unveiled a novel phenomenon highlighting the high momentum, two-dimensional propagation of photoluminescence emissions intricately coupled with surface lattice resonances
- Lysine Acetylation Regulates OsECT3 in Rice Cold Responseby Bioengineer on June 21, 2025 at 12:01 am
In the relentless pursuit to enhance crop resilience amid escalating climate unpredictability, a groundbreaking study from rice researchers uncovers a sophisticated molecular switch that governs how plants respond to cold stress. At the heart of this discovery lies a deeper understanding of N^6-methyladenosine (m^6A), the most prevalent internal modification on eukaryotic messenger RNA, and how
- Stem cell therapy: a potential cure for hearing loss?by Roohi Mariam Peter on June 20, 2025 at 1:00 pm
As stem cell research gains momentum, researchers are looking at ways to use the therapy to treat hearing loss. The post Stem cell therapy: a potential cure for hearing loss? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Special Episode: The 2025 BIO International Conventionby Dylan Kissane on June 20, 2025 at 8:00 am
In this week’s episode we meet three innovators on the floor in Boston and find out what their BIO experience has been like The post Special Episode: The 2025 BIO International Convention appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- 10 cultured meat companies driving sustainable food in 2025by Willow Shah-Neville on June 18, 2025 at 1:00 pm
Learn more about 10 of the top cultured meat companies in biotech looking to pave the way for a sustainable future. The post 10 cultured meat companies driving sustainable food in 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- From undruggable to oral therapy: The rise of STAT6 degradersby Jules Adam on June 18, 2025 at 8:00 am
Delve into the STAT6 degrader technology and what it could bring to inflammatory and allergic disease treatment. The post From undruggable to oral therapy: The rise of STAT6 degraders appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Six kidney disease companies you should know about in 2025by Willow Shah-Neville on June 17, 2025 at 1:00 pm
Discover six kidney disease companies actively working on innovative treatments that could make a difference to patients' lives. The post Six kidney disease companies you should know about in 2025 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Did Novo open the Canadian market to GLP-1 generics?by Jules Adam on June 16, 2025 at 1:00 pm
Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a small fee? The post Did Novo open the Canadian market to GLP-1 generics? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- A new era in migraine treatment: Innovative drugs redefining the fieldby Willow Shah-Neville on June 13, 2025 at 1:00 pm
Discover the new migraine medications, such as monoclonal antibodies and gepants, that are changing migraine treatment for the better. The post A new era in migraine treatment: Innovative drugs redefining the field appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Alex Telford on AI, drug discovery, digital twins, and the most interesting questions in biotechby Dylan Kissane on June 13, 2025 at 8:00 am
In this episode Alex Telford, co-founder of Convoke, explains the work he is doing before opening the door to his insatiable curiosity about the biotech industry. The post Alex Telford on AI, drug discovery, digital twins, and the most interesting questions in biotech appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Behind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure?by Jules Adam on June 11, 2025 at 12:00 pm
On the occasion of its deal with Cure51, find out about NVIDIA's biotech strategy as it gets more and more involved in the industry. The post Behind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Can gene therapy treat blindness and vision loss?by Roohi Mariam Peter on June 11, 2025 at 8:25 am
Since the approval of Luxturna, there has been a wave of companies developing treatments with the potential to cure different forms of genetic blindness. The post Can gene therapy treat blindness and vision loss? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Pushing biotech forward in France: 18 companies to know aboutby Jules Adam on June 10, 2025 at 1:00 pm
France is at the forefront of innovative biotech and Paris has become a vibrant startup ecosystem. Here are 18 top French biotech companies! The post Pushing biotech forward in France: 18 companies to know about appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- First antibiotic in 50 years to tackle superbug nears approval: what’s going on in the field?by Roohi Mariam Peter on June 9, 2025 at 1:00 pm
Antibiotic development has seen a slump in recent decades. Now, after 50 years, a new antibiotic has been created to tackle bacterial infections. The post First antibiotic in 50 years to tackle superbug nears approval: what’s going on in the field? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.
- Protecting Your Drug Patent in Global Markets: Strategies and Challengesby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 27, 2025 at 9:19 am
Navigating the Complex World of Global Drug Patents: Strategies and Challenges Ahead As a pharmaceutical professional, you know how crucial it is to protect your innovative drug patents in the global market. With the rise of international trade and the... Source
- Drafting Drug Patent Applications for Biologic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 26, 2025 at 11:45 am
The Complex World of Biologic Drugs: Navigating Patent Applications As a biotech professional, you're likely no stranger to the intricacies of developing life-saving treatments. But when it comes to biologic drugs, the process can be particularly chall... Source
- Successfully Patenting Drug Combinations: Strategies and Challengesby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 26, 2025 at 9:57 am
Unlocking the Power of Combination Therapies: Strategies for Successful Patenting As a pharmaceutical professional, you know that combination therapies have revolutionized the treatment of complex diseases. By pairing two or more active ingredients, yo... Source
- Effective Strategies for Generic Drug Price Settingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 25, 2025 at 9:17 am
The Secret to Setting the Right Price for Your Generic Medications As a generic drug manufacturer, you're constantly looking for ways to stay ahead of the competition and bring affordable medications to market. But have you ever wondered how to set the... Source
- Optimizing the Generic Drug Supply Chain: Strategies for Successby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 11:56 pm
Unlocking Efficiency in the Generic Drug Supply Chain As the pharmaceutical industry continues to evolve, the generic drug supply chain has become a critical component of ensuring timely and affordable access to life-saving medications. However, naviga... Source
- FDA Updates: What Do the Latest Changes Mean for Generic Drug Approval?by Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 8:55 pm
Breaking News: FDA Updates - What Do the Latest Changes Mean for Generic Drug Approval? As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic drug approval. Re... Source
- Regulatory Challenges in the Latin American Generic Drug Marketby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 24, 2025 at 4:10 pm
Breaking Down Barriers: Navigating Regulatory Challenges in Latin America's Generic Drug Market As the demand for affordable generic medications continues to grow, Latin America has emerged as a critical region for pharmaceutical companies looking to e... Source
- Analyzing the cost-effectiveness of biosimilars in different healthcare systemsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 23, 2025 at 11:27 am
The Future of Affordable Healthcare: Can Biosimilars Deliver? As healthcare professionals, we're constantly on the lookout for innovative solutions to improve patient outcomes while reducing costs. One promising approach is the use of biosimilars – bio... Source
- How to Achieve High-Quality Standards in Generic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 20, 2025 at 11:21 am
Ensuring the Highest Quality in Generic Medications: A Crucial Step in Healthcare As the global demand for affordable healthcare continues to rise, generic medications have become a vital lifeline for millions of people worldwide. However, with the inc... Source
- The Role of Quality Assurance in Generic Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 19, 2025 at 11:07 am
The Unseen Heroes of Generic Medicines: The Crucial Role of Quality Assurance As we navigate the complex world of pharmaceuticals, it's easy to overlook the unsung heroes behind the scenes. But today, I want to shine a spotlight on the Quality Assuranc... Source
- DrugChatter: Can lurbinectedin treat ovarian cancer?by DrugChatter on February 19, 2025 at 6:44 am
Can Lurbinectedin Treat Ovarian Cancer? A Comprehensive Review Ovarian cancer is a devastating disease that affects thousands... https://www.Drugchatter.com/chat/25460/can-lurbinectedin-treat-ovarian-cancer/ Source
- Regulatory considerations for biosimilar clinical efficacy trialsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 18, 2025 at 3:27 pm
Unlocking the Potential of Biosimilars: Navigating Regulatory Considerations for Clinical Efficacy Trials As the pharmaceutical industry continues to evolve, biosimilars have emerged as a game-changer in the quest for affordable and accessible treatmen... Source
- The basics of drug patent searchingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 18, 2025 at 10:38 am
Unlock the Secrets of Drug Patent Searching: A Beginner's Guide As a professional in the pharmaceutical industry, staying ahead of the curve is crucial. One of the most critical aspects of this is understanding the world of drug patents. But have you e... Source
- Navigating the Generic Drug Approval Process: A Comprehensive Guideby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 17, 2025 at 10:33 am
Unlocking the Path to Generic Medication Approval: A Step-by-Step Guide As a healthcare professional or a business leader in the pharmaceutical industry, you're likely aware of the complex landscape surrounding generic medication approval. With the eve... Source
- Strategies for successful biosimilar-to-biosimilar switchingby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 16, 2025 at 4:04 pm
The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, one question on everyone's mind is: how can we make the most of this opportunity? One strategy that's gaining traction is biosimilar-to-biosimilar s... Source
- Study Reveals Key Predictors of Early Patent Challenges for FDA-Approved Drugsby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 14, 2025 at 11:40 am
The Hidden Factors Behind FDA-Approved Drugs' Patent Challenges As a healthcare professional or a pharmaceutical industry expert, you're likely no stranger to the complex world of drug patents. But have you ever wondered what sets some FDA-approved dru... Source
- The Role of Partnerships in Generic Drug Developmentby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 13, 2025 at 9:12 am
Breaking Down Barriers: The Power of Partnerships in Generic Drug Development As the pharmaceutical industry continues to evolve, one thing is clear: collaboration is key. In the world of generic drug development, partnerships are playing an increasing... Source
- DrugChatter: Does fish oil interact with vascepa?by DrugChatter on February 12, 2025 at 9:10 pm
Does Fish Oil Interact with Vascepa? A Comprehensive Guide As the world becomes increasingly aware of the importance of... https://www.Drugchatter.com/chat/45752/does-fish-oil-interact-with-vascepa/ Source
- How to Manage Generic Drug Development Timelines: Strategies for Successby Insights: DrugPatentWatch - Find Your Next Blockbuster on February 12, 2025 at 9:10 am
The Art of Timing: Mastering Generic Drug Development Timelines As a seasoned professional in the pharmaceutical industry, you know that navigating the complex landscape of generic drug development can be a daunting task. One of the most critical facto... Source
- DrugChatter: How does lipitor affect white wine?by DrugChatter on February 11, 2025 at 4:56 pm
The Impact of Lipitor on White Wine: A Comprehensive Guide As a popular cholesterol-lowering medication, Lipitor (atorvastatin)... https://www.Drugchatter.com/chat/37341/how-does-lipitor-affect-white-wine/ Source